-
-
-
-
-
-
-
Barclays launches U.S. biopharma coverage with four preferred picks
-
-
-
-
-
-
-
Baird Reiterates Underperform Rating on Amgen (AMGN), '3Q25 Financials Look Mostly Solid'
-
-
-
-
-
-
-
BMO Capital: 'Strong Print Sets Amgen (AMGN) Shares Back on Track'
-
-
-
-
-
-
-
Amgen beats Q1 expectations, issues solid full-year outlook
-
-
-
-
-
-
-
Amgen (AMGN) Tops Q4 EPS by 27c, Beats on Revenue; Offers FY25 EPS Guidance
-
-
-
-
-
-
-
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
-
-
-
-
-
-
-
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
-
1,198,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

